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INTRODUCTION
The stunned myocardium, a reperfused myocardium after
brief ischemic episodes, exhibits a prolonged impairment of
systolic as well as diastolic function, despite the absence of
cell necrosis (1). The myocardial stunning usually recovers
spontaneously and requires no therapy. However, if the stun-
ning is severe or involves parts of the left ventricle large enough
to cause impairment of global ventricular function, it can be
reversed with several inotropic agents, such as dobutamine,
epinephrine, amrinone, a phosphodiesterase III inhibitor, and
calcium chloride (CaCl2) (2-4).
A transient myocardial ischemia may induce a marked
endothelial dysfunction, which results in decreased coronary
flow reserve and vasodilator responsiveness (5-7). Further-
more, the postischemic myocardium shows normal oxygen
consumption (MVO2), despite the depressed contractile func-
tion, i.e., increased oxygen cost of contractility (8). In this
context, inotropic drugs may alter coronary vascular responses
and hence affect myocardial oxygen balance in stunned myo-
cardium. A previous study indeed demonstrated in postis-
chemic canine myocardium that mechanical function was not
as tightly coupled as coronary blood flow (CBF) and MVO2,
and thus oxygen extraction (EO2) was rather increased during
inotropic stimulation with dobutamine (9).
It has been also demonstrated that ischemia and reperfu-
sion injury may dampen inotropic responses to  -adrenergic
stimulation (10). Moreover, an intracellular Ca2+ overloading
during ischemia and reperfusion has been implicated in the
pathogenesis of myocardial stunning (11). Since dobutamine
and epinephrine exhibit their inotropic activity through  -
adrenergic stimulation to increase intracellular Ca2+ availabil-
ity, their inotropic potency may be diminished in postischemic
myocardium. On the contrary, the inotropic activity of amri-
none may not be similarly affected. Furthermore, adminis-
tration of CaCl2 may augment calcium overload and deteri-
orate the regional function in postischemic myocardium. The
present study was aimed to determine the effects of dobu-
tamine, epinephrine, amrinone, and CaCl2 on regional oxy-
gen balance and mechanical function in postischemic stunned
myocardium. 
MATERIALS AND METHODS
The study was approved by the Institutional Review Board
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Effects of Inotropic Drugs on Mechanical Function and Oxygen 
Balance in Postischemic Canine Myocardium: Comparison of 
Dobutamine, Epinephrine, Amrinone, and Calcium Chloride
Brief ischemic episodes that induce myocardial and coronary endothelial dysfunc-
tion may alter the responses to inotropic drugs. To determine the effects of inotropic
drugs in stunned myocardium, the coronary blood flow (CBF), myocardial oxygen
consumption (MVO2), and regional mechanical function in response to intracoronary
dobutamine, epinephrine, amrinone, and calcium chloride (CaCl2) were measured
before (normal) and 30 min after a 15-min-period occlusion of the left anterior descend-
ing artery (stunned) in an open-chest canine model. Percent segment shortening
(%SS) and post-systolic shortening (%PSS) were determined. Myocardial extrac-
tion of oxygen (EO2) and lactate (Elac) was calculated. The inotropic drugs increased
%SS, CBF, and MVO2 in normal myocardium. Epinephrine and amrinone decreased,
while dobutamine and CaCl2 did not affect EO2. The ischemia and reperfusion itself
significantly reduced %SS and Elac, and increased %PSS. In stunned myocardium,
the responses to inotropic drugs were not significantly altered, except that they pro-
gressively reduced %PSS and epinephrine did not affect EO2. These findings indi-
cate that a brief episode of ischemia does not affect the mechanical and metabolic
coronary flow responses to inotropic drugs, although it abolishes direct vasodilator
responses to epinephrine. 
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of Experimental Animal Research. Mongrel dogs of either
sex, weighing 17-35 kg, were anesthetized with an intravenous
bolus of thiopental sodium (10-15 mg/kg). After tracheal
intubation, anesthesia was maintained with halothane (1.0%
end-tidal; Datex, Helsinki, Finland) in 100% oxygen via
positive pressure ventilation. Tidal volume and respiratory
rate were adjusted to maintain the end-tidal CO2 concentra-
tion of 4.5-5.5%. To obtain muscular relaxation, vecuronium
bromide was used (0.1 mg/kg as a bolus, followed by a con-
tinuous infusion at 0.05 mg/kg/h). Body temperature and
electrocardiogram were continuously monitored. Ringer’s
lactate solution was intravenously administered (5 mL/kg/hr).
A left thoracotomy was performed via the fifth intercostal
space to suspend the heart in a pericardial cradle. The instru-
ments were implanted in and around the heart as shown in
Fig. 1. Doppler transit time flow probe (Transonic System
Inc., Ithaca, NY, U.S.A.) was placed around the main pul-
monary artery for measurement of cardiac output, and another
flow probe was placed around the left anterior descending
coronary artery (LAD) just distal to the first diagonal branch
for continuous blood flow measurement. A rubber band was
placed around LAD immediately distal to the flow probe to
serve as an occluder. For the infusion of drugs, a 24-gauge
catheter was inserted into the proximal LAD. A pair of ultra-
sonic dimension transducers (Medical Research Technology,
Gaithersburg, MD, U.S.A.) was implanted approximately
10 mm apart in the subendocardium of the anterior wall that
demonstrated cyanosis during a brief test occlusion of LAD.
A catheter-tipped micromanometer (SPR-524, Millar Instru-
ments, Houston, TX, U.S.A.) was inserted directly into the
left ventricle via an apical incision for measurement of left
ventricular pressure (LVP). The first derivative of LV pres-
sure (dP/dtmax and -dP/dtmin) was obtained by electronic dif-
ferentiation.
The right femoral artery was cannulated for measurement
of aortic pressure with a catheter-tipped micromanometer
and for blood sampling. An 18-gauge catheter was inserted
into the left atrium for the measurement of luminal pressure
(Datex, Helsinki, Finland), and a 24-gauge catheter into the
anterior interventricular vein at the same level as the LAD
occluder for measurement of coronary venous oxygen and
lactate concentrations (12).
Oxygen (Gem Premier; Instrumentation Laboratory, Lex-
ington, MS, U.S.A.) and lactate concentrations (Vitros 950;
Ortho-Clinical Diagnostics, Rochester, NY, U.S.A.) were
measured in blood drawn simultaneously from the coronary
vein and artery. MVO2 of the anterior myocardial wall was
calculated by multiplying the arteriovenous oxygen difference
by total LAD flow. EO2 or myocardial lactate extraction (Elac)
(in percent) was calculated by dividing the arteriovenous differ-
ence by the arterial content. Plasma Ca2+ concentrations were
also measured from the anterior interventricular venous blood
using blood gas analyzer (Gem Premier; Instrumentation
Laboratory, Lexington, MS, U.S.A.). 
Experimental protocol
After a sufficient stabilization period of 60 min, pre-infu-
sion mechanical and hemodynamic data were collected. Simul-
taneous measurements of arterial and coronary venous oxygen
and lactate contents (metabolic data) were made. The animals
then received intracoronary infusions of either dobutamine
(n=11; 0.05, 0.125, and 0.375  g/mL CBF), epinephrine
(n=10; 0.004, 0.01, and 0.03  g/mL), amrinone (n=10; 2,
5, and 10  g/mL), or CaCl2 (n=11; 0.10, 0.25, and 0.75 mg/
mL) with a syringe pump (STC 524, Terumo, Japan). The
concentration ranges for dobutamine, amrinone, and CaCl2
were selected because they have been shown previously to
produce a comparable dose-dependent increase of %SS when
given intracoronarily in normal myocardium (2, 13). The
range of epinephrine had been demonstrated in pilot studies
to cause an increase of %SS comparable with that observed
during dobutamine infusion. The blood concentrations for
each inotropic agent examined include the clinical dose range
(dobutamine, 0.1-0.2  g/mL; amrinone 2-7  g/mL) (14, 15).
Each inotropic drug was infused for 3 to 5 min in incremental
doses administered 8 to 10 min apart each. Measurements
were made at the end of each dose, and the mechanical data
were obtained 5 min after each dose. Following one series of
experiment in normal myocardium, a 15-min LAD occlusion
and subsequent reperfusion were made to stun the myocardi-
um, as described by previous investigators (2, 7). Approxi-
mately 30 min after the onset of reperfusion, when hemody-
namic and flow values were stable, the same infusion protocol
in each group was repeated. Inotropic drugs were infused at
Fig. 1. Schematic presentation of the experimental preparation.
LAD, left anterior descending coronary artery; LCX, left circum-
flex coronary artery; IVC, intravenous catheter; IAC, intra-arterial
catheter; UDT, ultrasonic dimension transducers.
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0.3-2.0 mL/min. The intracoronary infusion rate of inotropic
drug was calculated by multiplying the desired coronary blood
concentration by LAD flow rate.
Data acquisition and analysis
Blood flows, segmental dimension of anterior wall, and
LV and mean aortic pressures were continuously monitored.
End-systolic segment length (ESL) was determined at the
point approximately 20 msec before peak negative LV dP/dtmin,
and end-diastolic segment length (EDL) was determined at
the onset of left ventricular isovolumetric contraction (16).
Regional myocardial contractility was determined using per-
cent segment shortening (%SS, [(EDL-ESL)/EDL]×100).
Percent post-systolic shortening (%PSS) as a regional diastolic
function was calculated by [(LminD-ESL)/(EDL-LminD)]×100,
where LminD=minimum length during diastole. Coronary
perfusion pressure was calculated by the difference of left atrial
pressure from aortic diastolic pressure.
At the end of the experiment, the heart was stopped by
intra-atrial injection of concentrated potassium chloride solu-
tion. The area supplied by LAD artery was defined by injec-
tion of Evans blue into the vessel at the site of the flow trans-
ducer. Careful weighing of the stained muscle allowed mean
flow to be calibrated in mL/min per 100 g of muscle. The
LAD perfusion territory was 27.6±6.2% of total left ven-
tricular mass. 
Statistical analysis
All data are presented as mean±SD. Statistical analysis
of the data was performed by two-way analysis of variance
(ANOVA) for repeated measures followed by Dunnett’s t
test. Comparisons between normal and stunned myocardi-
um were made by paired Student’s t-test. Significance was
assumed when p<0.05.
RESULTS
Of the 58 animals instrumented, eight were excluded from
data analysis because of pre-ischemic lactate production. One
of 12 animals given dobutamine, 2 of 12 given epinephrine,
2 of 12 given amrinone, and 3 of 14 given CaCl2 died due to
ventricular fibrillation during coronary occlusion or immedi-
ately after the onset of reperfusion. They were also excluded. 
Variable Drug
Drug dose
Low Medium High
Preischemic
baseline
Postischemic
baseline
Drug dose
Low Medium High
HR Dobutamine 130±16 129±16 128±15 128±15 126±15 125±16 125±16 126±15
(beats/min) Epinephrine 124±14 123±14 124±14 125±13 128±14 127±13 125±13 125±17
Amrinone 121±20 120±20 122±20 122±19 123±16 122±14 122±14 122±13
CaCl2 132±16 131±18 131±17 131±21 133±18 133±19 134±18 139±23
MAP Dobutamine 87±12 89±12 90±14 92±21 84±10 84±10 84±12 86±19
(mm Hg) Epinephrine 87±12 87±14 87±12 87±12 85±10 85±10 84±10 84±10
Amrinone 87±13 88±12 87±12 86±12 84±98 4 ±98 4 ±98 3 ±10
CaCl2 87±12 87±12 89±13 92±15 84±10 84±10 84±10 84±8
dP/dtmax Dobutamine 1,769±307 1,913±381 2,094±526* 2,481±918* 1,574±488
� 1,652±301 1,834±352* 2,181±756*
(mm Hg/s) Epinephrine 1,734±239 1,776±255 1,861±268* 2,118±292* 1,442±275
� 1,497±298 1,585±299* 1,852±431*
Amrinone 1,754±362 1,771±382 1,830±375* 1,943±415* 1,467±304
� 1,554±307 1,667±317* 1,823±346*
CaCl2 1,685±497 1,749±489 1,873±547* 1,987±646* 1,316±190
� 1,403±203 1,488±266* 1,787±251*
dP/dtmin Dobutamine 2,244±453 2,192±319 2,225±525 2,255±832 1,968±503
� 1,845±337 1,928±549 2,074±903
(mm Hg/s) Epinephrine 2,243±425 2,237±471 2,226±441 2,159±444 1,958±319
� 1,978±342 1,951±374 1,991±583
Amrinone 2,085±313 2,117±307 2,111±336 2,119±319 1,762±247
� 1,767±234 1,809±250 1,805±231
CaCl2 2,480±501 2,526±504 2,495±438 2,421±544 2,149±372
� 2,165±438 2,090±429 2,182±426
LAP Dobutamine 5.1±1.5 5.1±1.5 5.0±1.3 4.9±1.5 6.1±1.5 6.0±1.4 5.8±1.4 5.8±1.5
(mm Hg) Epinephrine 4.5±1.3 4.8±1.4 4.7±1.3 4.5±1.2 5.5±1.4 5.4±1.3 5.2±1.3 5.1±1.3
Amrinone 5.3±1.8 5.5±1.8 5.3±2.0 5.3±2.1 6.4±2.4 6.3±2.4 6.1±2.3 5.8±2.3
CaCl2 5.2±1.0 5.1±1.0 5.3±1.0 5.3±1.2 5.9±0.9 5.8±0.9 5.4±0.9 5.2±0.9
CI Dobutamine 2.6±0.5 2.7±0.5 2.7±0.5 2.7±0.6 2.4±0.3 2.4±0.3 2.4±0.3 2.5±0.4
(L/min/m
2) Epinephrine 2.4±0.5 2.4±0.5 2.4±0.5 2.5±0.4 2.3±0.4 2.3±0.4 2.3±0.4 2.4±0.5 
Amrinone 2.3±0.6 2.3±0.6 2.3±0.6 2.3±0.6 2.3±0.5 2.3±0.4 2.3±0.5 2.4±0.5
CaCl2 2.3±0.5 2.3±0.5 2.2±0.5 2.1±0.5 2.1±0.7 2.1±0.7 2.1±0.7 2.1±0.6
Table 1. Effect of intracoronary dobutamine (n=11), epinephrine (n=10), amrinone (n=10), and calcium chloride (n=11) on systemic
hemodynamics before (normal) and after a 15-min of coronary occlusion and subsequent reperfusion (stunned) in dogs
Data are mean±SD. Drug doses were 0.05, 0.125, and 0.375  g/mL for dobutamine, 0.004, 0.01, and 0.03  g/mL for epinephrine, 2, 5, and 10  g/mL
for amrinone, and 0.10, 0.25, and 0.75 mg/mL for CaCl2. HR, heart rate; MAP, mean aortic pressure; dP/dt max, maximum positive left ventricular pressure
derivative; dP/dt min, maximum negative left ventricular pressure derivative; LAP, left atrial pressure; CI, cardiac index. *p<0.05 vs. corresponding baseline
values; 
�
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Global ventricular function 
Table 1 shows systemic hemodynamic variables obtained
before and during intracoronary infusion of inotropic drugs.
Neither drugs significantly affected these variables in normal
myocardium, except for increases in dP/dtmax. LAD occlusion
Variable Drug
Drug dose
Low Medium High
Preischemic
baseline 
Postischemic
baseline
Drug dose
Low Medium High
%SS Dobutamine 17.2±3.3 18.9±3.5* 20.7±3.8* 22.9±4.2* 8.2±2.4
� 12.4±2.4* 17.3±3.3* 21.4±5.2*
Epinephrine 17.5±3.1 19.8±3.4* 21.3±3.7* 23.2±3.6* 9.0±4.0
� 11.0±4.0* 14.5±4.2* 20.2±5.0*
Amrinone 17.1±3.4 19.2±3.7* 20.6±4.0* 22.4±3.6* 7.9±3.9
� 11.4±4.9* 16.1±4.4* 19.6±4.7*
CaCl2 16.3±4.4 18.5±4.5* 20.3±4.9* 21.7±4.9* 7.4±4.5
� 9.9±5.3* 13.5±6.4* 19.6±4.7*
EDL (mm) Dobutamine 10.00±0.00 9.99±0.05 9.98±0.06* 9.96±0.07* 10.39±0.15
� 10.32±0.13 10.19±0.12* 10.08±0.11*
Epinephrine 10.00±0.00 9.97±0.03 9.94±0.03* 9.84±0.05* 10.30±0.13
� 10.21±0.12 10.12±0.12* 9.84±0.20*
Amrinone 10.00±0.00 9.93±0.02 9.88±0.03* 9.79±0.06* 11.02±0.17
� 10.22±0.11 10.27±0.13* 10.01±0.12*
CaCl2 10.00±0.00 9.95±0.10 9.89±0.24* 9.84±0.21* 10.48±0.40
� 10.18±0.42 10.08±0.20* 9.89±0.40*
ESL (mm) Dobutamine 8.24±0.10 8.10±0.09* 7.87±0.08* 7.70±0.11* 9.31±0.30
� 8.93±0.21 8.48±0.19* 8.12±0.19*
Epinephrine 8.18±0.10 7.98±0.09* 7.85±0.10* 7.51±0.11* 9.36±0.17
� 9.06±0.17* 8.65±0.15* 8.02±0.13*
Amrinone 8.17±0.18 7.92±0.15* 7.76±0.15* 7.53±0.16* 9.08±0.25
� 8.79±0.25 8.42±0.24* 7.98±0.23*
CaCl2 8.37±0.43 8.12±0.51* 7.91±0.48* 7.75±0.56* 9.70±0.71
� 9.16±0.72 8.71±0.74* 7.92±0.53*
%PSS Dobutamine 2.7±2.9 1.7±2.6 2.1±3.4 1.3±2.3 46.2±20.1
� 30.2±11.6* 14.6±3.7* 2.5±2.3*
Epinephrine 2.6±2.5 2.4±2.5 2.8±3.4 1.4±2.5 47.4±13.5
� 30.7±15.4* 17.9±7.7* 5.1±1.4*
Amrinone 2.6±3.1 2.8±3.5 3.5±4.0 1.6±2.3 41.5±12.4
� 29.5±11.6* 21.3±4.3* 5.3±1.7*
CaCl2 4.2±1.3 3.9±1.8 4.1±1.8 4.1±2.3 42.3±14.2
� 32.7±16.3* 16.6±9.0* 4.5±3.1*
Table 2. Effect of intracoronary dobutamine (n=11), epinephrine (n=10), amrinone (n=10), and calcium chloride (n=11) on regional seg-
ment data before (normal) and after a15-min of coronary occlusion and subsequent reperfusion (stunned) in dogs
Data are mean±SD. Drug doses were 0.05, 0.125, and 0.375  g/mL for dobutamine, 0.004, 0.01, and 0.03  g/mL for epinephrine, 2, 5, and 10  g/mL
for amrinone, and 0.10, 0.25, and 0.75 mg/mL for CaCl2. %SS, percent segment shortening; EDL, end-diastolic segment length; ESL, end-systolic seg-
ment length; %PSS, percentage post-systolic shortening. Length measures are normalized to an unstressed length of 10 mm at baseline. *p<0.05 vs.
corresponding baseline values; 
�
p<0.05 vs. normal myocardium. 
Variable Drug
Drug dose
Low Medium High
Preischemic-
baseline
Postischemic
baseline
Drug dose
Low Medium High
CBF Dobutamine 75±98 6 ±23 90±27* 112±11* 69±77 5 ±16 83±10 101±13*
(mL/min/100 g) Epinephrine 75±88 7 ±13* 97±14* 104±14* 71±11 77±14* 82±18* 90±20*
Amrinone 72±10 81±10 95±12 110±14 72±12 77±16 91±16 101±17
CaCl2 75±10 79±12 87±14 102±17 71±67 8 ±88 6 ±8 100±12
MVO2 Dobutamine 7.3±0.8 7.6±1.6 8.1±1.5* 8.9±1.9* 6.7±1.4 7.3±0.5* 7.3±1.5* 7.9±1.5*
(mL/min/100 g) Epinephrine 7.4±0.6 7.9±1.3 8.8±1.0* 9.4±1.3* 7.0±1.4 7.3±0.5* 7.7±2.0* 9.2±2.9*
Amrinone 6.7±1.0 7.5±1.6 8.3±0.9* 9.1±1.4* 6.3±1.0 7.3±0.5* 7.5±1.8 8.2±1.9
CaCl2 7.2±1.5 7.6±1.6* 8.5±1.8* 10.0±2.6* 6.1±1.2
� 6.9±1.6* 7.6±2.0* 8.8±2.5*
PaO2 (mm Hg) Dobutamine 431±72 445±33 450±76 474±93 492±99 465±68 477±92 455±84
Epinephrine 420±66 410±70 377±73 393±76 389±81 390±77 380±79 388±74
Amrinone 431±87 440±67 450±92 474±79 492±84 480±57 477±69 455±79
CaCl2 380±67 378±65 383±65 383±65 389±85 387±84 388±85 389±85
PvO2 (mm Hg) Dobutamine 32.7±5.4 32.7±3.5 34.3±3.7 33.9±2.8
� 34.2±3.6 33.3±3.2 33.5±3.2 34.2±3.1
�
Epinephrine 30.7 ±2.8 32.8±3.8* 34.3±4.0* 34.1±3.8* 32.0±3.7 32.7±3.9 33.7±5.0 33.6±5.4
Amrinone 33.3±2.4 35.7±2.4 * 37.1±3.4* 40.1±4.0* 34.3±3.0 36.7±3.1* 38.1±3.9* 40.0±4.0*
CaCl2 30.6±3.8 30.7±3.4 30.9±3.0
� 31.3±3.2
� 31.6±4.6 31.5±4.3 31.4±4.5
� 31.6±4.3
�
CPP (mm Hg) Dobutamine 74±13 75±12 75±11 75±87 2 ±87 0 ±97 2 ±12 71±9
Epinephrine 74±12 75±97 5 ±87 5 ±12 70±77 0 ±87 2 ±75 2 ±8
Amrinone 73±12 74±97 5 ±97 6 ±11 71±87 1 ±10 72±87 2 ±7
CaCl2 73±11 74±87 5 ±77 6 ±9   71±10 71±11 72±8   72±11 
Table 3. Effect of intracoronary dobutamine (n=11), epinephrine (n=10), amrinone (n=10), and calcium chloride (n=11) on coronary
blood flow (CBF) and oxidative metabolism before (normal) and after a 15-min of coronary occlusion and subsequent reperfusion
(stunned) in dogs
Data are mean±SD. Drug doses were 0.05, 0.125, and 0.375  g/mL for dobutamine, 0.004, 0.01, and 0.03  g/mL for epinephrine, 2, 5, and 10  g/mL
for amrinone, and 0.10, 0.25, and 0.75 mg/mL for CaCl2. MVO2, myocardial oxygen consumption; PaO2, arterial oxygen tension; PvO2, coronary venous
oxygen tension; CPP, coronary perfusion pressure. *p<0.05 vs. corresponding baseline values; 
�
p<0.05 vs. normal myocardium; 
�
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slightly increased heart rate and left atrial pressure, and de-
creased mean aortic pressure, dP/dtmax, dP/dtmin, and cardiac
index. They quickly returned toward the baseline values with
the onset of reperfusion, except dP/dtmax and -dP/dtmin, which
were kept lower than their preocclusion baseline values. In
stunned myocardium, the effects of inotropic drugs were
similar to those in normal myocardium. 
Regional ventricular function 
Table 2 shows the regional mechanical function in normal
and stunned myocardium. All inotropic drugs examined
caused dose-dependent increases in %SS and decreases in ESL,
while they did not affect %PSS, in normal myocardium. LAD
occlusion rapidly increased EDL (10.0 to 10.8-10.9) and
%PSS (2-5% to 72-79%), with systolic bulging apparent
within 1-3 min. Subsequent reperfusion produced a transient
increase in %SS followed by a gradual decline to 7.4-9.0%
(44-51% of preischemic baseline values) at 30 min of reper-
fusion, which did not differ between the groups. In stunned
myocardium, however, inotropic drugs resulted in changes
similar to those in normal myocardium, except for a progres-
sive reduction of %PSS. When inotropic drugs were stopped,
%SS returned rapidly toward, but not below, their postische-
mic baseline values in stunned myocardium (data not shown).
Coronary blood flow and oxidative metabolism
Table 3 shows the effects of inotropic drugs on MVO2,
CBF, and EO2 in normal and stunned myocardium. The
inotropic drugs in normal myocardium caused dose-depen-
dent increases in MVO2 and CBF. However, with epinephrine
and amrinone, CBF increased more markedly than did MVO2,
resulting in decreases in EO2 and increases in PvO2, whereas
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Fig. 3. Effect of intracoronary infusion of incremental doses of dobutamine (n=11), epinephrine (n=10), amrinone (n=10) or calcium chlo-
ride (n=11) on myocardial lactate extraction before (normal) and after a 15-min of coronary occlusion and subsequent reperfusion (stunned)
in dogs. Pre-baseline, preischemic baseline values; post-baseline, postischemic baseline values. Values are mean±SD. p<0.05 vs. *cor-
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Fig. 2. Effect of intracoronary infusion of incremental doses of dobutamine (n=11), epinephrine (n=10), amrinone (n=10) or calcium chlo-
ride (n=11) on myocardial oxygen extraction before (normal) and after a 15-min of coronary occlusion and subsequent reperfusion (stunned)
in dogs. Pre-baseline, preischemic baseline values; post-baseline, postischemic baseline values. Values are mean±SD. p<0.05 vs. *cor-
responding baseline values; vs. 
� amrinone.
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it increased in parallel with those of MVO2 with dobutamine
and CaCl2, resulting in EO2 and PvO2 unaltered (Fig. 2). After
LAD occlusion and reperfusion, CBF was not significantly
affected and MVO2 was slightly decreased from baseline values
of normal myocardium, despite the severely impaired contrac-
tile function. However, neither metabolic nor CBF responses
to inotropic drugs were significantly affected except that
epinephrine caused proportional increases in CBF relative to
MVO2, resulting in EO2 and PvO2 unaltered in the stunned
myocardium. Although significantly reduced by the ischemia
and reperfusion insult itself, Elac was not affected by inotropic
agents, except for that epinephrine caused a decrease in stunned
myocardium (Fig. 3). Plasma Ca2+ concentrations in the coro-
nary vein increased dose-dependently in normal and stunned
myocardium in the CaCl2 group (data not shown).
DISCUSSION
The present study showed that the inotropic drugs exam-
ined improved the regional systolic and diastolic functions
in stunned myocardium. Coronary vasodilator responses to
inotropic drugs were well maintained, although a direct vaso-
dilator response to epinephrine was abolished. Percent seg-
mental shortening returned to the postischemic baseline
values after discontinuation of inotropic drugs. Furthermore,
the myocardial contractile responses to the inotropic drugs
were not altered. These findings are in accord with those in
previous studies which also demonstrated a normal contrac-
tile reserve in response to inotropic stimulation in stunned
myocardium (2, 3). Taken together, a brief myocardial ischemic
insult may not significantly affect either  -adrenergic signal-
ing pathway or contractile response to Ca2+. In particular,
inotropic drugs including CaCl2, acting through an increase
in intracellular Ca2+ availability, are unlikely to deteriorate
mechanical function in the stunned myocardium, although
Ca2+ overloading is causally related with the pathogenesis of
myocardial stunning (11). In fact, viable cells regain control
of cytoplasmic Ca2+ very rapidly after ischemia and hence
intracellular Ca2+ levels return to a baseline value after 20 min
of reperfusion (17).
Although effects of inotropic drugs on the systolic func-
tion have been extensively studied in the stunned myocardi-
um, little information has been available about their effects
on diastolic function. In the present study, the drugs exam-
ined did not affect peak -dP/dtmin but produced a progressive
reduction of %PSS, a sensitive index of myocardial ischemia
(18). Schlack et al. (19) similarly observed that intracoronary
norepinephrine did not affect peak -dP/dtmin but reduced
post-ejection wall thickening in an open chest canine model.
The drugs may have improved early diastolic function. On
the other hand, peak -dP/dtmin has been demonstrated to reflect
ischemia-induced changes in contractility (i.e., peak ventricu-
lar pressure) rather than relaxation in regionally ischemic
canine hearts in an open chest canine model (20). The unaffect-
ed aortic pressure during the infusion of inotropic drugs in
the present study may be related to unaltered peak -dP/dtmin.
The reduced contractile function in stunned myocardium
has been associated with an unaltered MVO2 (8). If the con-
tractile function increases at a higher energy cost in stunned
myocardium, one would expect an elevated CBF for a given
level of contractility (assuming an unchanged EO2). How-
ever, the present study showed that CBF in relation to seg-
ment shortening was comparable in normal and stunned
myocardium. Chiu et al. (21) have demonstrated that regional
inotropic stimulation with isoproterenol restores synchrony
and regional work in stunned myocardium, without greatly
affecting regional MVO2 in dogs. They speculated that the
myocardial stunning produced asynchrony between force
development and segment shortening, thereby decreasing
systolic regional work (but not total work) to a greater extent
than MVO2. It is likely that inotropic drugs do not increase
total mechanical work but reclaim the synchrony. They may
not cause greater increases in CBF relative to regional work
in stunned myocardium. 
An endothelial dysfunction has been demonstrated after a
brief ischemic episode (5-7). However, in the present study,
the degree of CBF increases in response to inotropic drugs
did not differ between the normal and stunned myocardium,
with the exception of epinephrine which increased CBF in
parallel with MVO2. Buffington and Rothfield (3) similarly
observed an appropriate increase of CBF when regional con-
traction was stimulated by CaCl2in stunned porcine myocardi-
um. Taken together, in stunned myocardium, inotropic drugs
do not interfere with normal metabolic vasoregulation, by
which CBF is maintained in proportion to the myocardial
oxygen demand. It is unlikely that the inotropic drugs directly
affect coronary vascular tone even after a brief ischemic insult.
Nitric oxide (NO) has been known to mediate  -adrener-
gic dilation of resistance coronary vessels in dogs (22), and
peripheral vasodilation induced by amrinone in rat thoracic
aorta (23). Although EO2 was progressively decreased by
epinephrine in normal myocardium, it was unchanged in
stunned myocardium, suggesting that an ischemic insult
abolished its vasodilator effect (Fig. 2). It has been shown that
endothelium-dependent vasodilation involving NO is impaired
in stunned coronary endothelium (7). The abolished vasodila-
tor effect of epinephrine may be related to a diminished NO
production. In contrast, amrinone increased CBF in stunned
myocardium, the degree of which did not differ from that in
normal myocardium. Amrinone causes vasodilation in part
via release of endothelium-derived NO in rat thoracic aorta
(23). The maintenance of direct vasodilator response in stunned
myocardium may then indicate that NO does not mediate
the amrinone-induced vasodilation in coronary circulation. 
Myocardial lactate extraction was progressively decreased
with increasing doses of epinephrine in stunned myocardium
in the present study, suggesting an anaerobic metabolism738 K.Y. Yoo, H. Kim, C.W. Jeong, et al.
(Fig. 3). Stahl et al. (24) observed an increased heterogeneity
of oxygen extraction with very low venous oxygen saturation
in stunned myocardium despite patent microvasculature and
normal perfusion, implying either focally impaired perfusion
or increased metabolic activity. Epinephrine may have caused
focal microcirculatory changes with localized areas of tissue
hypoxia and anaerobic metabolism, despite the unaltered coro-
nary venous oxygen tension. However, lactate production was
more pronounced with epinephrine than with other three
drugs, despite comparable increases in MVO2 and CBF, in
stunned myocardium. It is unlikely that the impaired myocar-
dial perfusion appreciably limited oxidative metabolism dur-
ing epinephrine infusion. One more likely explanation may
include the metabolic effect of epinephrine on glucose. Totaro
and Raper (25) observed that after cardiopulmonary bypass
epinephrine causes systemic lactic acidosis in some patients
without apparent tissue ischemia. They speculated that epi-
nephrine inhibited pyruvate dehydrogenase through  -2
adrenoceptor agonistic effects and thus pyruvate shunted
toward lactate to preserve intracellular energy supply. It is
suggested that epinephrine may have impaired pyruvate meta-
bolism, resulting in an increased lactic acid production in
stunned myocardium.
There are several limitations in the present study. First,
halothane, instead of pentobarbital that has no direct coro-
nary or myocardial effect, was used to maintain anesthesia
during the study. Volatile anesthetics have been shown to
enhance recovery of postischemic myocardium (26). Halothane
may have some protective effects against ischemia and reper-
fusion injury of the myocardium and therefore altered the
response to inotropic drugs. In addition, volatile anesthetics
have been shown to directly produce coronary vasodilation
in vivo (27). However, it has been demonstrated that responses
to inotropic drugs under halothane anesthesia do not differ
from those under fentanyl-midazolam anesthesia in post-
ischemic myocardium in dogs (28). Second, in the present
study, inotropic drugs were administered before and after
LAD occlusion. CaCl2 and phosphodiesterase III inhibitor
(i.e., amrinone) have been demonstrated to precondition myo-
cardium against postischemic contractile dysfunction (29).
CaCl2 or amrinone administered before LAD occlusion may
have then altered its contractile responsiveness of postischemic
myocardium. However, the responses to CaCl2 in stunned
myocardium were similar regardless of whether it was admin-
istered before LAD occlusion or not, indicating that precon-
ditioning effects of CaCl2 are minor or null. Third, the time
course of recovery of postischemic, reperfused myocardium
was not evaluated to verify the constancy of regional segment
shortening in the previously ischemic zone during the time
period corresponding to drug infusion (30-70 min of reper-
fusion). However, regional contractile function (%SS) remained
constant between 30 and 90 min of reperfusion in an open-
chest canine model similar to ours (30). Furthermore, %SS
returned to the preinfusion baseline level after cessation of
inotropic drug infusion. Finally, heart rate and systemic blood
pressure (coronary perfusion pressure) were not controlled
during the study. Changes in these systemic hemodynamic
variables during infusion of inotropic drugs may increase MVO2
and CBF. However, neither drug affected aortic pressure, heart
rate, and coronary perfusion pressure throughout the study.
In conclusion, the inotropic drugs examined improved the
regional systolic and diastolic functions in the postischemic
stunned myocardium in a dose-dependent manner, as was
in the normal myocardium. The enhanced regional functions
were accompanied by increases in CBF, which were not affect-
ed by an ischemia and reperfusion insult, except for an aboli-
tion of direct coronary vasodilator effect of epinephrine. 
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